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Editorial 
Patenting Human Genes: The Myriad Controversy 
The controversy over human gene patents was reignited in March 2010 when a US Federal District Court decided 
that isolated human gene sequences are not patentable.• An appeal is pending, although the US Department of 
justice filed a friend-of-the-court brief in the case in late October, arguing that such gene sequences should not be 
patenrable.2 Because this case may eventually find its way to the US Supreme Court, the ruling could have signifi-
cant implications for gene-based medical therapies and for the biotechnology industry overall. It is therefore im-
portant to assess both the past and present context of this controversy, taking into account scientific research, 
health care access, and ethical concerns. 
Patents are government grants that give their owners the right to exclude anyone else from making, using, or 
selling the inventions they describe.3 To be eligible for a patent, the invention must be new, useful, and not obvious 
to someone working in the same field as the inventor.4 Laws of nature, physical phenomena, and abstract ideas are 
not patentable, but, according to the US Supreme Court, "anything under the sun that is made by man" is poten-
tially patentable.5 For example, a microorganism as it exists in nature is not patentable, but a version of that mi-
croorganism that has been genetically modified by man is. The US Patent and Trademark Office (USPTO) relies 
on this reasoning when issuing patents on isolated human genes~ ences, because human intervention is required 
to extract and purify them. 6 The European Union takes a similarly open stance toward gene patents and has issued 
a directive permitting isolated human gene sequences to be patented·. 7 Not surprisingly, gene patents have flourished. 
It is estimated that nearly 20% of human genes are associated with at least one US patent and that the number of 
DNA-related patents exceeds 40,000.8 
The current controversy over gene patents involves Myriad 6enetics, Inc., a biotechnology company that owns 
patents on isolated forms of 2 human genes, BRCA 1 and BRCA2, which have been linked to hereditary breast and 
ovarian cancer. As the owner of the patent, Myriad can pr vent others from using BRCA.l and BRCA2 in research, 
diagnostic, and therapeutic applicaJions. Myriad alSo has the ability to charge high prices to companies wishing 
to use these genes. Thus, the American ivil Liberties Union and the Public Patent Foundation filed a lawsuit claim-
ing that Myriad's patents were invalid., ti fleC:l biomedical research and diagnostic testing, and limited patients' 
access to medical care. The court agreed\vith the plaintiffs and found that isolated gene sequences are not patent-
able because they are not "markedly different" from the gene sequences as they exist in nature. 1 This was a surpris-
ing result, given that the matter of the patentability of isolated human gene sequences in the United States had been 
considered settled. While this case could be dismissed as an aberration, certain to be overturned or curtailed on 
appeal, other judges also have questioned the patentability of isolated gene sequences.9 As noted, the US Depart-
ment of justice has taken the position that such sequences should not be patentable,2 Accordingly, there is a real 
possibility that US courts will bar the patenting of human genes. Such a decision would place the United States in 
opposition to the European Union, and because the USPTO and its European counterpart, the European Patent 
Office (EPO), are among the largest patent offices in the world, 10 the resulting discordance could have profound 
implications for international policy. 
Although the Myriad case is concerned with genetic diagnostic testing, the District Court ruling calls into ques-
tion the validity of numerous patents that have been issued for other gene-based inventions, including gene-based 
biologic therapeutics. Many existing patented biologic drugs are biotech blockbusters, such as human insulin and 
insulin analogues, the rheumatoid arthritis drug etanercept, and the anemia drug erythropoietin. While the patents 
for such blockbuster agents generally cover more than the isolated and purified gene sequences on which they are 
based, the uncertainty over the scope of patent protection for biologic drugs could deter potential investment, re-
tarding the development of new gene-based therapies and adversely affecting the biotechnology industry. 
Given the impact of a potential ban on gene patenting, we need to further consider the arguments for and against 
such patents. Some opponents claim that human gene patents hinder scientific research, because investigators hop-
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ing to work with patented genes need to seek permission from the patent owners, thereby increasing costs and inef-
ficiencies. These costs, they suggest, may become so prohibitive that researchers will stop working with patented 
genes altogether. However, these claims have not yet been substantiated. In fact, there is little evidence that gene 
patents are actually having a deterrent effect on biotechnology research, ll,tl suggesting that various stakeholders 
may be using licensing agreements or other workarounds to facilitate research. 
From the standpoint of health care access, some critics of gene patenting argue that if a particular patented gene 
therapy or diagnostic test is deemed medically necessary, a patient will have little choice but to obtain the treatment 
or test from the patent owner or the owner's licensee. Indeed, there is evidence that patenting of diagnostic tests 
does restrict patients' options.B Although such restrictions could increase patient burden and costs, this effect is 
not unique to human gene patents; any patents granted to health care products can have such effects. Thus, the 
high cost of patented therapies is a drawback of the patent system as a whole and is not specific to gene patents. 
Afrer all, our patent system is based on the premise that patent exclusivity is needed to incentivize invention and 
innovation. Pharmaceutical companies have long contended that patent and market exclusivity allows them to 
recoup the costs of drug development and finance new research. 13 While gene patents may play a crucial role in 
promoting biotechnology innovation, there is insufficient evidence to determine whether the patent system is the 
optimal way of encouraging such innovation. 
Furthermore, some posit that the human genome is qualitatively different from other naturally occurring entities 
and is even distinct from the DNA of plants and other animals. Therefore, the argument goes, human dignity should 
preclude anyone from owning patents on human genes.14 Moreover, if the uman genome is part of man's common 
heritage and if individuals have an inalienable right to ownership of their bodies, including their genes, what right 
does any single individual have to own part of the genome?lS,16 !he difficulty with these arguments is that the 
patent owner merely owns the isolated gene and does not con o( the- genetic information encoded by that gene. 
In fact, these moral objections were made with respect to ~yria 's gene patents in opposition proceedings before 
the EPO, although they were ultimately rejected.17,18 Perhaps the,underlying thrust of these arguments is that by 
allowing patent owners to control isolated gene sequences, we may unwittingly be enabling them to control the 
encoded genetic information common to us all. 
A final decision in the Myriad case may be a-f«;w years off, depending on whether the US Supreme Court decides 
to weigh in. But are we, as a society, prepared for this <Jecision when important questions remain unanswered? For 
example, more evidence is needed to detetmine w ether gene patents actually impede the development, commer-
cialization, and/or utilization of important therapies and diagnostic tools. We need to critically consider whether 
controlling an isolated gene sequence translat~s into de facto control of the genetic information encoded by that 
sequence. How different is an isolated gene sequence from the gene sequence as it resides in the human body? The 
scientific community has a responsibility to enrich the debate on this controversial topic by providing empirically 
based, thoroughly deliberated answers to these and other questions. The answers will ultimately help inform the 
important decision society must make regarding the propriety of patenting human genes. 
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